A recent phase 3 clinical trial published in Annals of Internal Medicine supports the use of canagliflozin for treating type 2 diabetes in children and adolescents. The study involved 171 participants aged 10-18 years with inadequate glycemic control, who received either oral canagliflozin or a placebo for 52 weeks.
Continue reading “Phase 3 study supports use of canagliflozin for type 2 diabetes in children and adolescents”